MarketCap
Facebook
X
TelegramAnnual report 2024
added 12-27-2025
OrganiGram Holdings Revenue 2011-2026 | OGI
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue OrganiGram Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 160 M | 162 M | 146 M | 79.2 M | 86.8 M | 80.4 M | 12.4 M | 5.71 M | 6.13 M | 81.1 K | - | - | - | - |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 162 M | 81.1 K | 73.8 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Drug manufacturers industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
28 K | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
80.8 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
194 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
19.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.76 M | - | 0.86 % | $ 117 M | USA |
 |
Aurora Cannabis
ACB
|
175 M | $ 3.32 | 0.3 % | $ 86.3 M |  Canada |
 |
China Pharma Holdings
CPHI
|
4.53 M | $ 0.57 | -9.62 % | $ 9.95 M |  China |
 |
Catalent
CTLT
|
4.38 B | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
169 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
46.7 M | $ 2.58 | 2.38 % | $ 1.34 B | Canada |
 |
DURECT Corporation
DRRX
|
8.55 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
1.05 B | $ 8.01 | -0.5 % | $ 410 M | USA |
 |
Endo International plc
ENDP
|
2.01 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
5.18 M | - | - | $ 36.6 M | USA |
 |
Pacira BioSciences
PCRX
|
542 M | $ 23.2 | 2.43 % | $ 1.07 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
874 K | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
191 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
10.4 M | $ 3.13 | 2.62 % | $ 44 M | USA |
 |
Bausch Health Companies
BHC
|
8.76 B | $ 4.99 | -2.25 % | $ 1.82 B | Canada |
 |
Perrigo Company plc
PRGO
|
4.25 B | $ 9.64 | 0.73 % | $ 1.34 B | USA |
 |
Harrow Health
HROW
|
272 M | $ 35.2 | 3.53 % | $ 1.29 B | USA |
 |
OptiNose
OPTN
|
71 M | - | - | $ 1.08 B | USA |
 |
Evolus
EOLS
|
297 M | $ 4.43 | -5.34 % | $ 286 M | USA |
 |
Rockwell Medical
RMTI
|
83.6 M | $ 1.03 | 0.98 % | $ 24 M | USA |
 |
SCYNEXIS
SCYX
|
20.6 M | $ 0.9 | 2.8 % | $ 44.9 M | USA |
 |
Sundial Growers
SNDL
|
946 M | $ 1.37 | 0.74 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
14.3 M | $ 2.34 | -8.24 % | $ 2.9 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
317 M | - | -39.89 % | $ 27.7 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.13 K | $ 6.1 | 4.1 % | $ 241 M | USA |
 |
Tilray
TLRY
|
627 M | $ 6.66 | 3.26 % | $ 4.12 B | Canada |
 |
PetIQ
PETQ
|
1.1 B | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
8.21 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
123 M | - | - | $ 5.07 M | USA |
 |
Veru
VERU
|
16.9 M | $ 2.29 | -0.43 % | $ 309 M | USA |
 |
Jupiter Wellness
JUPW
|
702 K | - | - | $ 33.6 M | USA |
 |
TherapeuticsMD
TXMD
|
1.3 M | $ 2.29 | -0.87 % | $ 23.9 M | USA |
 |
Viatris
VTRS
|
15.4 B | $ 13.36 | 0.53 % | $ 16 B | USA |
 |
Radius Health
RDUS
|
230 M | - | - | $ 1.42 B | USA |
 |
Lannett Company
LCI
|
341 M | - | 1.15 % | $ 7.11 M | USA |
 |
cbdMD
YCBD
|
19.5 M | $ 0.77 | 1.06 % | $ 3.32 M | USA |
 |
Organogenesis Holdings
ORGO
|
482 M | $ 2.41 | -2.43 % | $ 317 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
25 M | - | - | $ 193 M | Canada |
 |
Canopy Growth Corporation
CGC
|
269 M | $ 0.96 | -0.87 % | $ 103 M | Canada |
 |
Assertio Holdings
ASRT
|
119 M | $ 16.51 | 17.93 % | $ 106 M | USA |
 |
Recro Pharma
REPH
|
94.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
86 K | - | - | $ 55.5 M | USA |